A new study carried out in pig cells suggests previous infection with swine influenza virus (SIV) can protect against the development of porcine respiratory coronavirus (PRCoV) if there is a zero- or three-day interval between infections.
A team of researchers from universities in California and Texas has found immunization rates for children in Texas for a wide range of diseases, including polio and measles, have dropped steeply during the COVID-19 pandemic.
A small molecule STING agonist was highly protective against the virus that causes COVID-19 and likely other coronaviruses
The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical biotechnology company based in San Diego, CA, to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI will be led by Professor Sujan Shresta, Ph.D., a member of the Institute’s Center for Infectious Disease and Vaccine Research.
UAB has established an interdisciplinary hub for research and patient care in the study of immunity.
In a new study, scientists at The Hong Kong University of Science and Technology (HKUST) have revealed that most T cell epitopes known to be targeted upon natural infection are seemingly unaffected by current SARS-CoV-2 variants.
Researchers are finding new details on the complex dynamics involved in how organisms sense an infection from pathogens. The researchers found that worms can sense changes in their metabolism in order to unleash protective defenses, even if they don’t directly sense an incursion from pathogens.
Spring has officially sprung, which means warmer weather, fresh blooms and the start of seasonal allergies.
In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world. The results are striking: human T cells can target more than 1,400 sites on the SARS-CoV-2 virus.
Along with a first-place winner, there are two honorable mentions in the Vasculitis Foundation’s (VFs) 2021 Recognizing Excellence in Diagnostics (V-RED) award program.
People who have had a mild case of COVID-19 are left with long-term antibody protection against future disease, according to a study from researchers at Washington University School of Medicine in St. Louis.
UC San Diego School of Medicine researchers identify how the body regulates and prevents constant skin inflammation.
Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I.
Within the next decade, the novel coronavirus responsible for COVID-19 could become little more than a nuisance, causing no more than common cold-like coughs and sniffles. That possible future is predicted by mathematical models that incorporate lessons learned from the current pandemic on how our body’s immunity changes over time. Scientists at the University of Utah carried out the research, now published in the journal Viruses.
A study of more than 3 million insured U.S. adult patients under 65 found that nearly 3% take immunosuppressive drugs that may elevate risk for severe COVID-19 symptoms and hospitalization if they became infected. There is growing evidence that immunosuppressive drugs may also reduce the COVID vaccine's efficacy.
Researchers have identified specific influenza targets that could be used to better protect Indigenous people from experiencing severe influenza disease through a universal, T cell-based vaccine.
Institute of Human Virology at the University of Maryland School of Maryland scientists, who are also members of the Global Virus Network (GVN), a coalition comprised of human and animal virologists from 63 Centers of Excellence and 11 Affiliates in 35 countries, and colleagues today published a perspective proposing that live attenuated vaccines (LAVs), such as those for tuberculosis, measles, and polio, may induce protective innate immunity that mitigate other infectious diseases, triggering the human body’s natural emergency response to infections including COVID-19 as well as future pandemic threats.
In the largest U.S. study of venom allergy and mastocytosis prevalence, Michigan Medicine researchers found that people with venom allergy are nearly 10 times more likely to suffer the bone marrow disorder that causes higher risk of fatal reactions. They also found that elevated levels of tryptase, a chemical secreted by allergy cells, may predict if a person is at higher risk for reaction to immunotherapy.
Reporters and bloggers are invited to join top nutrition researchers and practitioners for a dynamic virtual program at NUTRITION 2021 LIVE ONLINE. The flagship meeting of the American Society for Nutrition runs June 7–10, 2021 and features research announcements, expert discussions and more.
A groundbreaking study led by engineering and medical researchers at the University of Minnesota Twin Cities shows how engineered immune cells used in new cancer therapies can overcome physical barriers to allow a patient’s own immune system to fight tumors. The research could improve cancer therapies in the future for millions of people worldwide.
Researchers have developed first-in-class small-molecule inhibitors against a key leukemia protein, ASH1L.
Artificial food colorants can cause disease when the immune system has become dysregulated, Icahn School of Medicine at Mount Sinai researchers report. The study, published in Cell Metabolism in May, was the first to show this phenomenon.
Research published in Nature reveals insights into how the body maintains balance with “good” gut bacteria that allows these microbes to flourish in the intestine but keeps them out of tissues and organs where they’re not supposed to be.
Scientists at the Weizmann Institute and the Israel Institute for Biological, Chemical and Environmental Sciences took a novel tack to investigating SARS-CoV-2’s powerful ability to infect, finding that the virus deploys an apparently unique three-pronged strategy to take over the cell’s protein-synthesis abilities. The work could help develop effective Covid-19 treatments.
Following a national search, Roswell Park Comprehensive Cancer Center has promoted Pawel Kalinski, MD, PhD, to Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology and Senior Vice President for Team Science.
A new approach to tackling viruses by targeting the 'control centre' in viral RNA could lead to broad spectrum anti-viral drugs and provide a first line of defence against future pandemics, according to new research at the University of Birmingham.
A University of Kentucky College of Medicine professor has been awarded a $1.9 million NIH grant for his research on the body’s immune response to sepsis, which could potentially help to improve therapies for the common disease.
Scientists examining the remains of 36 bubonic plague victims from a 16th century mass grave in Germany have found the first evidence that evolutionary adaptive processes, driven by the disease, may have conferred immunity on later generations of people from the region.
Using whole exome sequencing, CHOP researchers discovered the genetic mutation responsible for a condition that prevents patients from making B cells and antibodies to fight infections. The study describing the condition, which CHOP researchers named PU.1 Mutated agammaglobulinemia (PU.MA), was published today in the Journal of Experimental Medicine.
In a recent perspective article, pathologists outline how the immunome — all of the genes collectively expressed by an individual's immune cells — holds the potential to provide researchers and physicians with unprecedented insight into an individual's health. Collecting that information from large numbers of patients could one day facilitate diagnostics via a near-universal blood test and pave the way to targeted therapies for a wide variety of conditions.
Every year the World Health Organization recognizes the last week of April as World Immunization Week – a time to celebrate the millions of lives saved and the eradication of multiple diseases because of vaccines. However, access to vaccines is still a barrier for many children in our community, so public health experts with The University of Texas Health Science Center at Houston (UTHealth) are hitting the ground to bring lifesaving immunizations directly to them.
UC San Diego School of Medicine researchers discovered one way in which SARS-CoV-2 hijacks human cell machinery to blunt the immune response, allowing it to establish infection, replicate and cause disease.
Tiny molecules called nanobodies, which can be designed to mimic antibody structures and functions, may be the key to blocking a tick-borne bacterial infection that remains out of reach of almost all antibiotics, new research suggests.
Researchers at the Pritzker School of Molecular Engineering (PME) at the University of Chicago have designed a completely novel potential treatment for COVID-19: nanoparticles that capture SARS-CoV-2 viruses within the body and then use the body’s own immune system to destroy it.
Wolters Kluwer, Health announced today the publication of two new, fully open access journals under its Lippincott® portfolio as part of an ongoing collaboration with the Chinese Medical Association (CMA). Cardiology Discovery and Infectious Diseases & Immunity will accelerate the dissemination, exchange, and utilization of scientific research results in their respective fields.
Victoria Blaho, Ph.D., assistant professor in the Immunity and Pathogenesis Program at Sanford Burnham Prebys, has received the first-ever Lina M. Obeid Award for her promising research on the biology of sphingolipids. The award honors Obeid, a pioneer in the field of sphingolipids and a fierce advocate for women in science. The award was presented at the 11th International Ceramide Conference on April 22, 2021.
The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them
Severe cases of COVID-19 can involve extensive inflammation in the body, and clinicians have wondered if this state is similar to what are called cytokine storm syndromes, in which the immune system produces too many inflammatory signals that can sometimes lead to organ failure and death.
COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mechanical ventilation more often.
Scientists have discovered a molecular pathway that counteracts the ability of some viruses to evade the immune response. The findings raise hope in generating better immune responses to viral infections, such as COVID-19, as well as to cancer.
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies, potentially in combination with immune tolerance therapies, to tame the immune response in some patients with severe hemophilia A.
McMaster University researchers Ali Ashkar and Sophie Poznanski have uncovered that changing the metabolism of natural killer (NK) immune cells allows these cells to overcome the hostile conditions found inside tumours and destroy advanced ovarian and lung cancer.
Combining immune-boosting drugs with radiation and surgery increased the survival and anticancer immune response in mouse models of mesothelioma in preclinical research by Princess Margaret Cancer Centre researchers.
A new study, led by the University of California, Irvine (UCI), reveals how chronic inflammation promotes muscle fibrosis, which could inform the development of new therapies for patients suffering from Duchenne muscular dystrophy (DMD), a fatal muscle disease.
In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.
Wheezing, coughing that doesn’t stop, a pale and sweaty face: clinically, severe asthma attacks look very similar from patient to patient. But biologically, not all severe asthma is the same—and a team of scientists has, for the first time, identified the key difference in people, a finding that has important implications for treatment.
You’ve probably heard that the first two vaccines approved for battling COVID-19 in the United States use a relatively new approach—injections of simple packets containing mRNA, a genetic material that instructs our cells to make coronavirus spike proteins. But the technology for generating sufficient amounts of those mRNA packets dates back to the 1980s, when F. William Studier, then a senior biophysicist at the U.S. Department of Energy’s Brookhaven National Laboratory, developed a way to harness the molecular machinery of a very different virus.
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or resistance to immune checkpoint inhibitors, drugs that help the body’s immune system recognize and attack cancerous cells.
A dysfunctional immune system significantly contributes to the development of cancer. Several therapeutic strategies to activate the immune system to target cancer cells have been approved to treat different types of cancer, including melanoma.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right